Skip to main content

AeroClean Receives FDA Clearance For Pūrgo™ Medical Grade Air Hygiene Technology

Written by Customer Service on . Posted in Public Companies.

FDA Clearance Provided After Review Of Patented Germicidal UV-C LED Air Purification Technology Proven Effective At Eliminating Harmful Airborne Microorganisms

PALM BEACH GARDENS, Fla., June 06, 2022 (GLOBE NEWSWIRE) — AeroClean Technologies (“AeroClean” or the “Company”) (Nasdaq: AERC), a leading air hygiene technology company and producer of patented UV-C LED technology inside its innovative air purification Pūrgo™ device, today announced that the U.S. Food and Drug Administration (FDA) has granted AeroClean’s Pūrgo technology 510(k) clearance, classifying it as a Class II Medical Device. The clearance was provided after a thorough review of the patented Pūrgo device, which utilizes patented germicidal UV-C LED air purification technology and is proven to eliminate 99.99% of harmful airborne microorganisms, including bacteria, fungi and viruses, like COVID-19. As experts in Indoor Air Quality (IAQ), AeroClean provides healthcare facilities, businesses, hospitality venues and government agencies with the highest medical grade air purification and air sanitization technology.

“We are proud to have been granted FDA clearance for AeroClean’s Pūrgo™ device and thank the administration for their in-depth review of our patented air hygiene technology,” said Jason DiBona, CEO of AeroClean. “As experts in indoor air quality, we aim to provide healthcare facilities, businesses, hospitality venues and government agencies with the highest medical-grade air purification and air sanitization technology. FDA clearance of our Pūrgo™ system, which is powered by our patented SteriDuct™ technology, represents a major step forward in significantly improving air quality where people meet, work and live.”

Pūrgo™ has been rigorously tested in a variety of laboratory test chambers and multiple real world indoor spaces. The patented technology uses hospital-grade HEPA filtration as well as optimized germicidal UV irradiation to provide supplemental, localized air cleaning and enhanced ventilation so businesses and organizations can cost-effectively comply in real-time with recent federal guidelines supporting healthy building initiatives and cleaner, safer indoor air.

Developed by medical professionals and aerospace engineers, the FDA-cleared Pūrgo™ solution goes beyond basic filtration, which has been the standard for indoor air purification for decades. Traditional air filtration systems only capture larger particles such as dust and pet hair and offer limited intermittent cleaning of indoor air, potentially increasing the exposure to fine particulate and harmful bioaerosols.

AeroClean is committed to help businesses and organizations improve IAQ for a healthier and safer world, so work, play, and life keeps going. For more information about AeroClean technology and Pūrgo™ solutions, visit: www.AeroClean.com.

About AeroClean Technologies:
AeroClean is a pathogen elimination technology company on a mission to keep work, play and life going—with continuous air hygiene products called, Pūrgo™ (pure-go). We create solutions for hospitals, offices, and many shared spaces as well as elevators, transportation and more. Pūrgo™ products feature SteriDuct™, a proprietary technology developed by our best-in-class aerospace engineers, medical scientists and innovators. Powered by SteriDuct™, our solutions are medical grade, eradicating viral, fungal, and bacterial airborne microorganisms. Our purpose is simple: to never stop innovating solutions that keep people healthy and safe, so life never stops. Learn more at aeroclean.com.

Media Contact
Drew Tybus
Drew@OakPR.com

Investor Relations Contact
Ryan Tyler
Chief Financial Officer, AeroClean
RTyler@AeroClean.com

or:
Brian Pinkston
MATTIO Communications
aeroclean@mattio.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.